Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.17 ^USD	-3.65%		+7.09%	-23.52%

Apr. 10	Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	CI
Mar. 19	Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	MT

Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 11, 2022 at 06:52 am EST

Leap Therapeutics, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 40.59 million compared to USD 27.51 million a year ago. Basic loss per share from continuing operations was USD 0.47 compared to USD 0.63 a year ago.

Diluted loss per share from continuing operations was USD 0.47 compared to USD 0.63 a year ago.

Latest news about Leap Therapeutics, Inc.

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	Apr. 09	CI
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	Mar. 19	MT
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration	Mar. 18	MT
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Transcript : Leap Therapeutics, Inc. - Special Call	Jan. 23
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium	Jan. 16	CI
Transcript : Leap Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	Jan. 10
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients	Jan. 02	CI
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating	Nov. 20	MT
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Top Premarket Decliners	23-10-16	MT
Top Premarket Decliners	23-10-09	MT
Baird Lowers Price Target on Leap Therapeutics to $20 From $30, Maintains Outperform Rating	23-08-15	MT
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating	23-07-13	MT
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients	23-07-12	CI
Raymond James Adjusts Price Target on Leap Therapeutics to $17 From $20, Keeps Outperform Rating	23-06-23	MT
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell Microcap Value Index	23-06-23	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell 3000E Value Index	23-06-23	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell 3000E Index	23-06-23	CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell Microcap Index	23-06-23	CI
Leap Therapeutics to Effect 10-for-1 Reverse Stock Split	23-06-20	MT
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting	23-05-25	CI
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI

Chart Leap Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.29 USD

Average target price

11.75 USD

Spread / Average Target

+257.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LEAP THERAPEUTICS, INC.	-23.52%	84.24M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs